staurosporine has been researched along with pci 32765 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angst, D; Beerli, C; Cenni, B; Dawson, J; Funhoff, EG; Gessier, F; Gutmann, S; Hinniger, A; Janser, P; Littlewood-Evans, A; Nuesslein-Hildesheim, B; Pulz, R; Scheufler, C; Vulpetti, A; Wälchli, R; Wieczorek, G; Zimmerlin, A | 1 |
| Abdel-Maksoud, MS; Alach, NN; Anbar, HS; El-Gamal, MI; El-Gamal, R; Oh, CH; Sbenati, RM; Shehata, MK; Tarazi, H; Zaraei, SO | 1 |
2 other study(ies) available for staurosporine and pci 32765
| Article | Year |
|---|---|
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Female; Humans; Mice; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein Structure, Tertiary; Rats; Rats, Inbred Lew; Sheep | 2020 |
Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Imidazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, ErbB-4; Structure-Activity Relationship; Thiazoles | 2021 |